



Leading innovation in biopharma manufacturing

Founded in 1980 by Dr Krishna M Ella and Mr Sushirva K Ella, Bharat Biotech is one of the largest vaccine and biopharmaceutical facilities of its kind in the Asia Pacific region spread across 70,000 square metres. Located in Genome Valley, Hyderabad, one of the biggest biotechnology clusters in India, Bharat Biotech is globally recognised for its innovative research on neglected infectious diseases, high quality manufacturing practices and quality governance.

Researchers and scientists at Bharat Biotech create some of the most promising vaccines, and biotechnologies to prevent infectious diseases and promote health among developing world populations.

The company specialises in product-oriented research and development. The production facilities are designed to produce safe and affordable viral, bacterial and

recombinant vaccines.

Bharat Biotech boasts the finest biotechnology and virology labs in the country. The highly efficient patented MMAR technology developed by Bharat Biotech, which eliminates ultra-centrifugation and the use of toxic reagents such as osmium tetroxide while increasing the recovery of antigenic proteins to levels highest in the world, played a vital role in bringing down the cost of the production of hepatitis B vaccine, making it affordable for millions across the country and other developing nations.

Bharat Biotech is the only production site in the country approved by the Korean Food and Drug Administration (KFDA). The company's manufacturing, control procedures and protocols, conform to stringent standards set by national and international authorities like The Food and Drug Administration (USFDA), The Medicines and Health Care Regula-

tory Agency of UK (MHRA), National Regulatory Authority (NRA) and World Health Organisation (WHO).

Apart from injectables, oral, ophthalmic and oyster filling facilities, it boasts a dedicated animal facilities to conduct virus tests and other toxicological tests. Bharat Biotech's state-of-the-art facilities with specialised laboratories and equipment comprise of 15 buildings.

The products manufactured and the capacity of the manufacturing plant per annum is as follows:

In vaccines space: Anti-rabies (10 million doses), hepatitis B (100 million doses of two brands), typhoid (20 million doses), Oral polio (100 million doses), Hib (10 million doses), DPT-HepB-HB (20 million doses), DPT-HepB (10 million doses), Hib (10 million doses)

In biopharmaceuticals space

The company produces r-EGF (1.4 million units of three brands), mesenchymal (8 million units), heparin (2 million units), interferon- α (1 million units) and IRS- α (1 million units)

Facilities at Bharat Biotech have been audited by more than 30 countries worldwide including Brazil, Colombia, Ethiopia, Saudi Arabia, Kazakhstan, Korea, Sri Lanka, Turkey, Ukraine, and Uganda.

The company exports products to over 80 countries. Over the last decade, Bharat Biotech delivered over 1.2 billion doses of vaccines to countries worldwide.

Bharat Biotech's mission is to offer affordable, safe and effective health-care solutions to combat mankind's dreaded illnesses and thus eradicate or at least control their occurrence in the years to come.